MEK抑制对BRAF/MEK抑制剂联合治疗BRAF突变黑色素瘤的贡献:随机开放标签III期COLUMBUS试验第2部分
COLUMBUS试验第2部分将晚期BRAF V600突变黑色素瘤患者按3:1随机分配至COMBO300组(encorafenib 300 mg每日一次+binimetinib 45 mg每日两次)或ENCO300组(encorafenib 300 mg每日一次)。COMBO300组258例,ENCO300组86例。结果显示COMBO300较ENCO300(第1+2部分合并)显著改善无进展生存期(中位12.9个月 vs 9.2个月,HR 0.74,95%CI 0.60-0.92,P=0.003),客观缓解率68% vs 51%,且3/4级不良事件更少。
要点
- COMBO300较ENCO300(第1+2部分合并)中位无进展生存期12.9个月 vs 9.2个月,HR 0.74(95%CI 0.60-0.92,P=0.003)。
- COMBO300客观缓解率68%(95%CI 62-74)vs ENCO300(第1+2部分合并)51%(95%CI 45-57)。
- COMBO300相对剂量强度更高,3/4级不良事件少于ENCO300。
核心结论
- COMBO300较ENCO300改善无进展生存期、客观缓解率和耐受性,证实binimetinib对疗效和安全性的贡献。
研究设计与样本
- COLUMBUS第2部分为随机、开放标签、III期试验,患者按3:1随机分配至COMBO300组或ENCO300组。
- COMBO300组258例接受encorafenib 300 mg每日一次+binimetinib 45 mg每日两次;ENCO300组86例接受encorafenib 300 mg每日一次。
- 按方案将ENCO300第1部分和第2部分数据合并(n=280)用于无进展生存期分析(关键次要终点),由盲态独立审查委员会(BIRC)评估。
主要发现
- COMBO300组中位无进展生存期(95%CI)为12.9个月(10.9-14.9),ENCO300(第1+2部分合并)为9.2个月(7.4-11.1),ENCO300(第2部分)为7.4个月(5.6-9.2)。
- COMBO300对比ENCO300(第1+2部分合并)的风险比(95%CI)为0.74(0.60-0.92;双侧P=0.003)。
- BIRC评估的客观缓解率(95%CI)COMBO300为68%(62-74),ENCO300(第1+2部分合并)为51%(45-57)。
- ENCO300中位随访时间:第1部分为40.8个月,第2部分为57.1个月。
- COMBO300相对剂量强度更高,3/4级不良事件少于ENCO300。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In COLUMBUS part 1, patients with advanced BRAFV600-mutant melanoma were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice a day (COMBO450), vemurafenib 960 mg twice a day, or encorafenib 300 mg once daily (ENCO300). As previously reported, COMBO450 improved progression-free survival (PFS) versus vemurafenib (part 1 primary end point) and ENCO300 (part 1 key secondary end point; not statistically significant). Part 2, requested by the US Food and Drug Administration, evaluated the contribution of binimetinib by maintaining the same encorafenib dosage in the combination (encorafenib 300 mg once daily plus binimetinib 45 mg twice daily [COMBO300]) and ENCO300 arms. METHODS: In part 2, patients were randomly assigned 3:1 to COMBO300 or ENCO300. ENCO300 (parts 1 and 2) data were combined, per protocol, for PFS analysis (key secondary end point) by a blinded independent review committee (BIRC). Other analyses included overall response rate (ORR), overall survival, and safety. RESULTS: Two hundred fifty-eight patients received COMBO300, and 86 received ENCO300. Per protocol, ENCO300 arms (parts 1 and 2 combined) were also evaluated (n = 280). The median follow-up for ENCO300 was 40.8 months (part 1) and 57.1 months (part 2). The median PFS (95% CI) was 12.9 months (10.9 to 14.9) for COMBO300 versus 9.2 months (7.4 to 11.1) for ENCO300 (parts 1 and 2) and 7.4 months (5.6 to 9.2) for ENCO300 (part 2). The hazard ratio (95% CI) for COMBO300 was 0.74 (0.60 to 0.92; two-sided P = .003) versus ENCO300 (parts 1 and 2). The ORR by BIRC (95% CI) was 68% (62 to 74) and 51% (45 to 57) for COMBO300 and ENCO300 (parts 1 and 2), respectively. COMBO300 had greater relative dose intensity and fewer grade 3/4 adverse events than ENCO300. CONCLUSION: COMBO300 improved PFS, ORR, and tolerability compared with ENCO300, confirming the contribution of binimetinib to efficacy and safety.
引用
- Ascierto PA, Dummer R, Gogas HJ, et al. Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. J Clin Oncol. 2023. PMID: 37506329. doi:10.1200/JCO.22.02322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。